PetMed Express (PETS)
(Delayed Data from NSDQ)
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.90 USD
+0.04 (1.04%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.90 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth D Momentum B VGM
Zacks News
Inogen Claims Top Position in Deloitte List on Solid Growth
by Zacks Equity Research
Inogen's (INGN) unique direct-to-customer business model has lent it a leading position in the United States.
QIAGEN (QGEN) Faces Declining HPV Sales, Intense Competition
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
TransEnterix (TRXC) Posts In-Line Loss in Q3, Sales Fall Y/Y
by Zacks Equity Research
TransEnterix's (TRXC) reports unimpressive Q3 results, thanks to the constriction of deferred service revenues.
Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife
by Zacks Equity Research
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.
Genomic Health (GHDX) Swings to Earnings in Q3, Revenues Lag
by Zacks Equity Research
Genomic Health (GHDX) gains from strong adoption of its Oncotype DX test in Q3.
Hill-Rom (HRC) Banks on Product Launches, Competition Rife
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation through research and development. A slew of product launches in the fourth quarter is encouraging.
Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.
Globus Medical (GMED) Q3 Earnings In Line, View Reiterated
by Zacks Equity Research
Globus Medical (GMED) reports in-line third-quarter numbers on the back of higher revenues from core international business.
Baxter Posts Solid Q3, Broad Product Spectrum Raises Hopes
by Zacks Equity Research
Baxter's (BAX) convenient kidney dialysis solutions, regenerative tissue products, 3-in-1 oXIRIS set for continuous renal replacement therapy are the latest additions to the extensive product portfolio.
SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
by Zacks Equity Research
VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
by Zacks Equity Research
Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.
DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull
by Zacks Equity Research
Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology (ALGN) consistently invests in R&D for product innovation.
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.
Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View
by Zacks Equity Research
Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.
Wright Medical (WMGI) Portfolio Solid, Lower Extremities Dull
by Zacks Equity Research
Wright Medical (WMGI) is focusing on product innovation through research and development. However, lackluster international performance of the Lower extremities segment is a matter of concern.
QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View
by Zacks Equity Research
QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
by Zacks Equity Research
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.
CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View
by Zacks Equity Research
CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.
Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline
by Zacks Equity Research
Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.